Contact

Plain Compass 74 Home About Services Risk Comparison Safety Checklist Regulatory Grey Zone Contact Field note / September 2026 Ibogaine And 5-meo-dmt In Mexico: Safety Brief Mexico’s availability is not proof of medical approval, clinical efficacy, or adequate safety. This is a plainspoken guide to risks, screening, regulation, and care standards for people considering, supporting, or researching psychedelic therapy. No dosing. No sourcing. No clinic endorsements. A treatment destination is not a clinical guarantee. Keep the distinction. Ibogaine’s defining concern is cardiac risk. 5-MeO-DMT’s concerns include acute psychological destabilization, interactions, aspiration, and inadequate response capacity. Start with the safety question Availability is not a care standard Ibogaine and 5-MeO-DMT in Mexico operate in a regulatory gray zone. Some facilities use general medical licenses and employ doctors, nurses, psychologists, or qualified medical professionals; there is no single, comprehensive federal system specifically accrediting psychedelic therapy clinics. A discussion of ibogaine treatment laws can help frame why legal status should not be mistaken for patient safety. Mexico has become a destination for addiction treatment and retreat-style care partly because its rules can appear less restrictive than those in the United States. That does not convert an experimental intervention into established medical care. The U.S. Food and Drug Administration explains its drug-development role through its drug development and approval process , a useful contrast when marketing language implies approval that is not present. People assessing a treatment center should ask for specifics: who screens patients, which medical protocols are used, how vital signs are monitored, what emergency equipment is on site, and how transfer to a hospital would work. Safety begins with answers that can be checked, not reassuring slogans. Ibogaine: a cardiac-risk intervention Understanding ibo

Contact

Keeping the signal clear